Innovación y competencia en el sector farmacéutico en la época de la medicina de precisión

• Jaume Puig-Junoy ^[1] ; Carlos Campillo-Artero ^[1]
  1. [1] Universitat Pompeu Fabra

     Universitat Pompeu Fabra

     Barcelona, España

     
• Localización: Papeles de economía española, ISSN 0210-9107, Nº 160, 2019 (Ejemplar dedicado a: Medicamentos, innovación tecnológica y economía), págs. 52-63
• Idioma: español
• Enlaces
  • Texto completo (pdf)
• Resumen
  • español

    En el contexto de la medicina de precisión, se analizan los problemas económicos asociados con la finalización de las patentes, las barreras a la entrada y las políticas de fomento de la competencia en los mercados de genéricos y de biosimilares, los cambios recientes en l+D de la industria farmacéutica y en el ciclo vital de los medicamentos, sus implicaciones relacionadas con los costes, la productividad, los beneficios y su impacto esperado en la productividad y rentabilidad de la industria, junto con el papel de los seguros, y las ventajas y limitaciones de los sistemas de pago basado en valor de medicamentos

  • English

    In the context of precision medicine, we analyze the economic problems associated with the patents expire, barriers to entry and policies to promote competition in the generic and biosimilar markets, the recent changes in R&D of the pharmaceutical industry and in the life cycle of medicines, their implications for costs, productivity and benefits, and their expected impacts on profitability of the industry, along with the role of insurance coverage, and the advantages and limitations o f t he valuebased payment systems.

• Referencias bibliográficas
  • Barlas, S. (2014). Are specialty drug prices destroying insurers and hurting consumers?: a number of efforts are under way to reduce price...
  • Belloni, A., Morgan, D. y Paris, V. Pharmaceutical expenditure and policies: past trends and future challenges. OECD Health Working Papers,...
  • Berndt, E. R., Dubois, P. (2016). Impacts of patent expiry on daily cost of pharmaceutical treatments in eight OECD countries, 2004-2010....
  • Campillo-Artero, C. (2014). Regaining HTA from oblivion: Improving and integrating the regulation of drugs, devices, diagnostics and surgical...
  • Campillo-Artero, C.— (2015). ¿Cuánto se innova?, Ges Clin Sanit,17, pp. 7-9.
  • Campillo-Artero, C.— (2016). Reformas de la regulación de las tecnologías médicas y la función de los datos de la vida real. En J. E. del Llano,...
  • Campillo-Artero, C., García-Armesto, S. y Bernal-Delgado, E. (2015). The merry-goround of new drugs´appraisal, pricing and reimbursement in...
  • Chandra, A., Garthwaite, C. y Stern, A. D. (2018). Characterizing the Drug Development Pipeline for Precision Medicines. NBER Working Paper,...
  • Cherni, N. I., Sullivan, R., Kerst, J. M. et al. (2015). A standardised, generic, validated approach to stratify the magnitude of clinical...
  • Comisión Europea (2018). Innovative payment models for high-cost innovative medicines. Report of the Expert Panel on effective ways of investing...
  • Del Paggio, J. C., Sullivan, R., Schrag, D. et al. (2017). Delivery of meaningful cencer care: a retrospective cohort study assessing cost...
  • DiMasi, J. A., Graboski, H. G. y Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal...
  • Dylst, P. (2017). European Biosimilar Medicines Markets – Policy Overview. Ed. Medicines for Europe (Biosimilar Medicines Group). Bruselas.
  • Experts in Chronic Myeloid Leukemia (2013). The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices...
  • Feifei, L., Zhao, Ch. y Wang, L. (2014). Molecular-targeted agents combination therapy for cancer: Developments and potentials. Int J Cancer,...
  • Garau, M. y Mestre-Ferrándiz, J. (2009). Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries. OHE Briefing....
  • Garau, M., Towse, A., Garrison, L. et al. (2011). Can and Should Value Based Pricing Be Applied to Molecular Diagnostics? London. Office of...
  • Gerber, A., Stock, S. y Charalabos-Markos, D. (2011). Reflections on the Changing Face of German Pharmaceutical Policy. Pharmacoeconomics,...
  • Grupo Génesis-Sociedad Española de Farmacia Hospitalaria (2016). Alirocumab y Evolocumab en Hipercolesterolemia. Informe para la Guía Farmacoterapéutica de...
  • Henrard, S. y Arickx, F. (2016). Negotiating prices of drugs for rare diseases. Bull WHO, 94, pp. 779-781.
  • Institute of Medicine (2011). Building a National Framework for the Establishment of Regulatory Science for Drug Development: Workshop Summary....
  • Jomi, C. (2018). Managed entry agreements and high cost medicines (European perspective). En Z. Babar, Equitable access to high-cost pharmaceuticals. London:...
  • Kaltenboeck, A. y Bach, P. B. (2018). Valuebased pricing for drugs: Theme and variations. JAMA, 319(21), pp. 2165- 2166.
  • Klebanoff, C.A., Yamamoto, T. N. y Restifo, N. P. (2014). Treatment of aggressive lymphomas with anti-CD19 CAR T cells. Nat Rev Clin Oncol,...
  • Komarova, N. L. y Boland, C. R. (2013). Calculated treatment. Nature, 499, pp. 291-292.
  • Kushnick, H. L. (2015). Pricing Cancer Drugs: When Does Pricing Become Profiteering? AMA J Ethics, 17(8), pp. 750-753.
  • Lakdawalla, D. N. (2018). Economics of the pharmaceutical industry. Journal of Economic Literature, 56(2), pp. 397-449.
  • Lobo, F. (2015). Políticas actuales de precios de medicamentos en Europa: panorama general. Madrid: Springer Healthcare.
  • Lobo, F. — (2017). La Economía, la innovación y el futuro del Sistema Nacional de Salud. Madrid: Funcas.
  • Mestre-Ferrándiz, J., Deverka, P., Pistollato, M. y Rosenberg, E. (2014). The Current Drug Development Paradigm: Responding to US and European...
  • Ministerio de Sanidad, Servicios Sociales e Igualdad (2017). Plan estratégico para el abordaje de la hepatitis c en el Sistema Nacional de...
  • Onakpoya, I. J., Spencer, E. A., Thompson, M. J. y Heneghan, C. J. (2015). Effectiveness, safety and costs of orphan drugs: an evidence-based...
  • Paris, V., Colbert, A. y Delaunay, N. (2017). Achieving the promise of precision medicine. En Organisation for Economic Cooperation and Development,...
  • Persson, U. y Norlin, J. M. (2018). Multi-indication and combination pricing and reimbursement of pharmaceuticals: Opportunities for improved...
  • Prasad, V. y Mailankody, S. (2017). Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval....
  • Prescrire International (2017). New products and new indications in 2016: a system that favors imitation over the pursuit of real progress....
  • Rejón-Parrilla, J. C., Hernández-Villafuerte, K. Shah, K., et al. (2014). The expanding value footprint of oncology treatments. London: Office...
  • Salas-Vega, S., Iliopoulos, O. y Messialos, E. (2017). Assessment of overall survival, quality of life, and safety benefits associated with...
  • Towse, A., Cole, A. y Zamora, B. (2018). The debate on indication-based pricing in the U.S. and five major European countries. OHE Consulting...
  • Van der Gronde, T. V., Uyl-de-Groot, C. A. y Pieters, T. (2017). Addressing the challenge of high-priced prescription drugs in the era of...
  • Voger, S., Gombocz, M. y Zimmerman, N. (2017). Tendering for off-patent outpatient medicines: lessons learned from experiences in Belgium,...
  • Volkinger, K. N., Kesselheim, A. S., Avorn, J. y Sarpatwari, A. (2017). Strategies that delay market entry of generic drugs. JAMA, 177(11),...
  • Wouters, O. J., Kanavos, P. G. y McKee, M. (2017). Comparing generic drug markets in Europe and the United States: prices, volumes and spending....